Spruce Biosciences Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Spruce Biosciences is a late-stage biotechnology company focused on developing therapies for neurological disorders with significant unmet medical needs. Its lead program, tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, targets a pediatric neurodegenerative condition with no approved treatments. The company is based in South San Francisco, California, and concentrates its research on science-led approaches aimed at affecting patient outcomes. 
 
 The primary market includes patients and clinicians addressing rare pediatric neurodegenerative diseases lacking approved therapies. In June 2026, Spruce Biosciences announced leadership appointments as it advances toward regulatory milestones and a potential U.S. commercial launch of TA-ERT.

Sign up for free to view info

Company overview Employee directory